SCHEMBL2858099

SCHEMBL2858099

CCCCCCN(CCCCN(CCCn1c(=O)[nH]c2ccccc2c1=O)C(=O)OC(C)(C)C)CCCn1c(=O)[nH]c2ccccc2c1=O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.54
HSD17B10 Q99714 6/20 0.48
KDM4E B2RXH2 5/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 3/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.47
MAPT P10636 4/20 0.46
GAA P10253 4/20 0.45
GLA P06280 3/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.44
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPK10 P53779 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861565 0.92 MPO (0.61) MPOHSD17B10KDM4EALDH1A1HPGD
SCHEMBL2862517 0.92 MPO (0.52) MPOHSD17B10KDM4EALDH1A1HPGD
SCHEMBL2855786 0.86 MPO (0.53) MPOHSD17B10KDM4EALDH1A1HPGD
SCHEMBL2858108 0.86 MPO (0.46) MPOHSD17B10KDM4EALDH1A1HPGD
SCHEMBL2862521 0.85 HSD17B10 (0.48) MPOHSD17B10KDM4EALDH1A1HPGD
SCHEMBL17598943 0.84 MPO (0.48) MPOHSD17B10KDM4EALDH1A1HPGD
SCHEMBL2861287 0.81 MPO (0.62) MPOHSD17B10KDM4EALDH1A1HPGD
SCHEMBL2853268 0.79 MPO (0.61) MPOHSD17B10KDM4EALDH1A1HPGD
SCHEMBL2861184 0.79 CNR2 (0.57) KDM4EALDH1A1MAPK1MAPTLMNA
SCHEMBL2857505 0.78 MPO (0.57) MPOHSD17B10KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9290480-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same Shin Poong Pharmaceuticals Co., Ltd. (KR) 2016-03-22 US claimed
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-04-25 US claimed
US-8404696-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-03-26 US claimed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP claimed
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2010-12-09 US claimed
EP-2239257-A2 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME Shin Poong Pharmaceutical Co. Ltd. (KR) 2010-10-13 EP claimed
US-9290480-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same Shin Poong Pharmaceuticals Co., Ltd. (KR) 2016-03-22 US disclosed
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-04-25 US disclosed
US-8404696-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-03-26 US disclosed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP disclosed
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2010-12-09 US disclosed
EP-2239257-A2 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME Shin Poong Pharmaceutical Co. Ltd. (KR) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME AQP4, PMP22, CNTN1 MPO 1589/4885HSD17B10 2598/4885KDM4E 2022/4885
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same AQP4, PMP22, CNTN1 MPO 1589/4885HSD17B10 2598/4885KDM4E 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.